Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Depreciation (2022 - 2025)

BioXcel Therapeutics has reported Accumulated Depreciation over the past 4 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $1.8 million for Q4 2025, up 19.97% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 19.97% YoY), and the annual figure for FY2025 was $1.8 million, up 19.97%.
  • Accumulated Depreciation for Q4 2025 was $1.8 million at BioXcel Therapeutics, up from $1.7 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for BTAI hit a ceiling of $1.8 million in Q4 2025 and a floor of $679000.0 in Q1 2022.
  • Median Accumulated Depreciation over the past 4 years was $1.2 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Accumulated Depreciation: surged 42.12% in 2023 and later rose 19.97% in 2025.
  • BioXcel Therapeutics' Accumulated Depreciation stood at $885000.0 in 2022, then skyrocketed by 34.8% to $1.2 million in 2023, then rose by 25.9% to $1.5 million in 2024, then rose by 19.97% to $1.8 million in 2025.
  • The last three reported values for Accumulated Depreciation were $1.8 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.